ACR Convergence 2025

October 24-29, 2025. Chicago, Illinois.

View by Number View by Title View Sessions

Abstract Number: 2298

When Imaging and Biopsy Disagree: Diagnostic Value of Doppler Ultrasound and Histologic Features beyond the Focus Score
Abstract Number: 2299

Real-world clinical effectiveness of rituximab rescue therapy in patients with progressive interstitial lung disease associated with primary sjögren’s syndrome
Abstract Number: 2300

Evaluation of the Ianalumab Treatment Effects on Major Salivary Glands of Patients With Sjögren’s Disease by Multimodal Ultrasound: Results From a Phase 2 Mechanistic Study
Abstract Number: 2301

Use of lived experiences in childhood Sjogren Disease to develop outcome measures for an N-of-1 treatment trial.
Abstract Number: 2302

Clustering by ESSPRI and PROMIS domain measures defines distinct subtypes and facilitates longitudinal assessment of patients with Sjogren’s disease
Abstract Number: 2303

Metabolic impact of low dose IL‐2 therapy for primary Sjögren’s Disease in a double‐blind, randomized clinical trial
Abstract Number: 2304

Updates in the local treatments in Primary Sjögren’s Syndrome “Efficacy and Safety”
Abstract Number: 2305

Predictors of Hospitalization and Emergency Department Visits Among Patients with Psoriatic Disease: Insights from the Forward Psoriasis Registry
Abstract Number: 2306

Prevalence and Clinical Significance of the Gastrointestinal Fat Halo Sign in Patients with Psoriatic Arthritis: A Cross-Sectional Study
Abstract Number: 2307

Peripheral Manifestations In Axial And Peripheral Spondyloarthritis: A Systematic Literature Review On Their Assessment In Clinical Trials
Abstract Number: 2308

Physical Function Mediates Most—but Not All—of the Effect of Disease Activity on Health-Related Quality of Life in Axial Spondyloarthritis: A 10-Year Longitudinal Analysis
Abstract Number: 2309

Lifestyle behaviours and disease activity in patients with psoriatic arthritis: the Dutch south west psoriatic arthritis study
Abstract Number: 2310

Neuropeptide influence in nociception and inflammation through immune system modulation in SPA patients
Abstract Number: 2311

Obstructive Sleep Apnea Syndrome in Patients with Psoriatic Arthritis and Its Relationship with Disease Activity and Comorbidities
Abstract Number: 2312

Sociodemographic Characteristics and Healthcare Utilization in Patients with IBD-Associated Arthritis vs. IBD Alone: A Nationwide Inpatient Analysis

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].